Clinical Trial Update: Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis [Phase 2]

View source ↗

Summary

Phase 2 study of Natrunix in HLA-B27 positive individuals with axial spondyloarthritis. The trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis

Drugs mentioned

• Natrunix

Snippet

Sponsor: XBiotech, Inc. | Conditions: Axial Spondyloarthritis | Phase 2 | Status: NOT_YET_RECRUITING